News
Actuate Therapeutics' elraglusib shows promise in metastatic pancreatic cancer. Upcoming FDA meeting may accelerate approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback